NCT05851547 - Dose Escalation For INtraprostatic LEsions | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 23, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions

Prostatic Neoplasms

Interventions

RADIATION

Prostate SBRT with Focal Boost

Prostate stereotactic body radiotherapy delivered to 27 Gy in 3 fractions on alternating days to uninvolved regions with up to 39 Gy in 3 fractions delivered to mpMRI-defined intraprostatic lesions

DRUG

Triptorelin Injection

Six months of androgen deprivation therapy for intermediate-risk localized prostate cancer and 24 months for high-risk localized prostate cancer

Trial Locations (1)

K1H 8L6

RECRUITING

The Ottawa Hospital Cancer Centre, Ottawa